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Background: Lipid lowering agent such as agonists of peroxisome proliferator-activated receptors (PPAR) are
suggested as neuroprotective agents and may protect from the sequelae of brain ischemic stroke. Although the
demonstration is not clearly established in human, the underlying molecular mechanism may be of interest for
future therapeutic purposes. To this end, we have used our well established rodent model of ischemia-reperfusion
pre-treated or not with fenofibrate or atorvastatin and performed a differential proteomics analyses of the brain and
analysed the protein markers which levels returned to “normal” following pre-treatments with PPARα agonists.
Results: In order to identify potential therapeutic targets positively modulated by pre-treatment with the PPARα
agonists, two-dimensional gel electrophoresis proteome profiles between control, ischemia-reperfusion and
pre-treated or not, were compared. The polypeptide which expression was altered following ischemia – reperfusion
but whose levels remain unchanged after pre-treatment were characterized by mass spectrometry and further
investigated by Western-blotting and immunohistochemistry. A series of 28 polypeptides were characterized
among which the protein disulfide isomerase reduction – a protein instrumental to the unfolded protein response
system - was shown to be reduced following PPARα agonists treatment while it was strongly increased in
ischemia-reperfusion.
Conclusions: Pre-treatment with PPARα agonist or atorvastatin show potential neuroprotective effects by inhibiting
the PDI overexpression in conjunction with the preservation of other neuronal markers, several of which are
associated with the regulation of protein homeostasis, signal transduction and maintenance of synaptic plasticity.
This proteomic study therefore suggests that neuroprotective effect of PPARα agonists supposes the preservation of
the expression of several proteins essential for the maintenance of protein homeostasis not necessarily directly
linked to PPARα known-regulated targets.
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Ischemic stroke is the second leading cause of death and
the first one of disability in adults of industrialized coun-
tries [1, 2]. In the acute phase of stroke, there is currently
one major therapeutic strategy using the tissue plasmi-
nogen activator of thrombolysis [3, 4]. To date, clinical tri-
als have not demonstrated any neuroprotective effect of a
single drug at the acute phase of ischemic stroke. Thus,
the interest has turned to alternative therapeutic strategies
such as preventive neuroprotection based on the induc-
tion of cerebral protection to ischemia prior to its occur-
rence. For that purpose, two families of antilipidemic
drugs, including fibrate and statin families likely exhibit a
neuroprotective effect in an experimental model of ische-
mic stroke [5, 6]. The clinical demonstration of efficacy of
fibrate in stroke is still under investigation [7] whereas sta-
tin therapy is more promising [1] and even recommended
for elderly patients who recently had a stroke or transient
ischemic attack [8].
The two families molecules have different signaling
pathway and their use in stroke therapy is based on their
neuroprotective way of action. The fibrate family contains
several compounds that are all peroxisome proliferator-
activated receptor alpha (PPARα) agonists. PPARα is one
of the three subtypes of the nuclear receptor PPAR that is
essential to regulation energy metabolism and vascular
homeostasis [9], and is, as the β/δ and γ subtypes, ex-
pressed in brain tissue [10]. Experimental data strongly
suggest that PPARs are interesting targets in ischemic
stroke [11]. The activation of PPARα by fibrates has been
demonstrated to induce neuroprotection, by reducing the
brain infarct volume [12] and by the modulation of several
pathophysiological pathways: inflammation, oxidative
stress, the amyloid cascade [13–16]. The activation of
PPARα by its ligands stimulates target gene transcription
via the formation of a heterodimer complex of transcrip-
tion factor with the retinoid X receptor (RXR) [17]. In the
brain, PPARα activation leads to the expression of target
genes such as Cu/Zn SOD or glutathione peroxidase
[18, 19] resulting in an increased redox state. Moreover,
PPARα activation represses NF-κB and the activator-
protein-1 signaling pathways [20] thereby down regulating
the inflammatory response and oxidative stress. Moreover,
Brain activation of PPARα has been described as poten-
tially neuroprotective in several models of brain patholo-
gies such as ischemic stroke or closed head injury [21, 22]
and this effect is abrogated by co-treatment by a PPARα
antagonist [12].
Statins were firstly developed as molecular inhibitor of
the hydroxyl methyl coenzyme A (HMG-CoA) reductase,
a key enzyme of cholesterol synthesis. Statins reduce syn-
thesis of endogenous cholesterol and isoprenoids, mole-
cules that modulate several cell functions [23]. Thus,
Chen and collaborators had shown that statin permit animproved functional recovery after stroke through a
statin-induced amplification of angiogenesis, neurogenesis
and synaptogenesis [24, 25]. The mechanisms underlying
such effect are multiple and in relationship with the pleio-
tropic effect of statins. For instance, statins activates the
PI3kinase/AKT and RAS/ERK pathways [26]. Phosphory-
lation of AKT and ERK transduces cell-surviving signal
[27]. These pleiotropic effects are, at least partly, mediated
by the activation of PPARα [16–28] and hence, the effect
of statins could overlap that of PPARα agonists.
Due to the pleiotropic molecular cascades induced by
those two pharmacological classes of hypolipidemic drugs
associated to their potential usefulness as neuroprotective
drugs in stroke, we investigated the modifications of the
brain proteome induced the pre-treatment with those
drugs before brain ischemia/reperfusion. This proteomics
analysis was performed in our model of brain ischemia-
reperfusion pre-treated or not with fenofibrate and ator-
vastatin. Using this approach we aimed to identify
metabolic pathway stimulate by these drugs and asso-
ciated to neuroprotection.
Results and discussion
2D Brain proteome analysis
For this assay, animals were divided in six experimental
groups: control group, fenofibrate treated group, atorva-
statin treated group, ischemia-reperfusion injury group,
fenofibrate treated and ischemia-reperfusion injury, ator-
vastatin treated and ischemia-reperfusion injury. In order
to potentially identify the major differences in between
groups and not the heterogeneity in between animals, the
brain tissues of the animals of each group were pooled
and processed for 2D analysis. The 2D gels were repeated
a minimum of three times in order to obtain at least three
gels that could be analyzed using Melanie III Software.
Gels were successively stained with Coomassie blue and
silver staining before being digitized. Examples of 2D pro-
files of rat brain proteomes are shown on Figure 1. The
overall profile is reproducible in between experimental
conditions showing that in the ischemia-reperfusion con-
ditions, the brain proteome is not altered by the experi-
mental procedure. Therefore, 2D gels were compared in
between control and ischemia-reperfusion and in groups
of animals treated or not with drugs. Gels were analyzed
with Melanie III software and differences were proc-
essed for mass-spectrometry identification. Three kinds
of differences were observed such as an increased or de-
creased expression or isoelectric point variations when
compared to the control condition. Three series of 28
polypeptides were isolated and characterized following
in-gel trypsin-digestion of the selected spots and mass
spectrometry identification (Table 1). In order to iden-
tify the protein markers modulated following thera-







Figure 1 Proteomics analysis of cortex from hypolipidemic drugs - treated rats under control or ischemia-reperfusion conditions. A.
The shown gels are representative of the observed results. Each condition was reproduced at least three times before spots excision and MALDI-TOF
analysis. 6 animals per group were included. B. Representation of the interactome obtained with CytoScape Freeware. The markers identified are
colored in red.
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First, we analyzed the mismatches between the control
group and the ischemia-reperfusion injury group. Second,
in order to identify potential therapeutic targets for neuro-
protection, we attempted to identify variations between
ischemia-reperfusion conditions with or without the
neuroprotective preconditioning treatments. Moreover,variations of the proteome profile should have been com-
parable to that observed in the control proteome pattern.
The modifications observed are summarized in the last
column of Table 1.
A major part of the proteins identified after 2D analysis
were submitted to variation 24 hours after cerebral ische-
mia-reperfusion injury (24 among the 28 polypeptides
Table 1 Proteins identified by MALDI-TOF analysis
Accession
number
Protein Function pI/MW (kDa) Peptides
match/%
Variation
P35213 14-3-3 isoform zeta, PKC inhibitor Signal transduction 5.5/28 9/40 ↑ I/R, ↑ Atorva
P35213 14-3-3 protein beta/alpha Signal transduction 4.8/28 7/31 ↑ Atorva, ↓ Feno
P45953 Acyl-CoA dehydrogenase,
very long chain specific
Lipid Metabolism, Mito 9.0/70.8 4/16 ↑ I/R
P84079 ADP rybosilation factor 1 Trafficking 6.3/20.7 4/16 ↑ I/R
Q9Z0U5 Aldehyde oxidase precursor Redox regulation 6.5/146.9 5/25 ↑↑ I/R, ↑I/R Atorva, ↑, I/R Feno
P37840 Alpha-synuclein Presynaptic/axon 4.7/14.5 4/11 ↓ I/R, ↓ Atorva
P23565 Alpha-internexin Intermediate filament 5.2/56.2 5/26 ↓ I/R
Q63754 Beta-synuclein Neuronal plasticity 4.5/14.3 5/17 ↑ I/R
Q05175 Brain acid soluble membrane
protein (NAP 22)
Growth cone/axon 4.5/21.8 4/15 ↑ I/R
O88767 DJ-1 Pleiotropic 6.3/20 5/31 ↓ I/R




5.9/57.6 4/17 ↑ I/R, ↓ Atorva
O35077 Glycerol-phosphate-deshydrogenase Metabolism 6.3/38 2/11 ↑ I/R
O35796 GCQ1QBP Glycoprotein Complement/Mito 4.8/30.7 4/21 ↓ I/R
P63039 HSP 60 Protein folding 8.2/58.08 5/14 ↑ I/R
Q07439 HSP 70.1/2 Protein folding 5.5/70.3 3/14 ↓ I/R
P34058 HSP 90 beta Protein folding 5.1/83.4 7/38 ↑ Feno
Q62689 Janus Kinase 2 Tyrosine kinase/
inflammation
7.1/130.5 7/30 ↓ I/R, ↑ Atorva
P42123 Lactate dehydrogenase B chain Metabolism 5.7/36.6 6/25 ↓ I/R
P40925 Malate dehydrogenase Metabolism 6.2/36.7 3/15 ↑ I/R
Q62599 Metastasis associated protein 1 Unknown brain function 9.2/79.4 4/26 ↓ I/R
P52590 Nucleoporine 107 Nuclear pore 5.3/107.2 4/26 ↓ I/R
P35704 Peroxiredoxine 2 Redox regulation 5.3/21.8 6/42 ↑ Feno
P31044 Phosphatidylethanolamine-binding protein Serine protease inhibitor 5.5/20.8 6/17 ↓ I/R
P35291 Rab16 Trafficking 5.0/22 4/25 ↑ Atorva, ↑ Feno
P49803 Regulator of G protein signaling 7 Signal transduction 8.3/55.7 4/50 ↑ I/R
P11507 Serca 2 Calcium Homeostasis 5.2/114.7 12/14 ↓ I/R
P21707 Synaptotagmin I Synapse 8.8/47.8 4/22 ↑ I/R
P47942 TUC-4 / TOAD 64 (DYPL/CRMP) Axonal guidance/
development
6.0/62.2 15/71 ↑ I/R
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most representative variation observed is an increase of
expression in the ischemia-reperfusion group. Among the
proteins increased in expression, several are involved in
the energetic metabolism of the cell such as aldehyde oxi-
dase precursor, or malate dehydrogenase precursor. A sec-
ond group was constituted with proteins involved in
intracellular signaling pathways: i.e. 14-3-3 ζ as PKC in-
hibitor, or the regulator of G protein signaling 7. Other
proteins are localized to the synapse and are important
structural proteins, such as α-synuclein, internexin and
synaptotagmin I. Proteins implicated in the folding were
also modulated, for instance HSP60 was increasedwhereas HSP70 was decreased in the ischemia-reperfusion
condition. Interestingly, HSP60, HSP70, HSP90 as well as
TOAD-64 were already identified in a rat middle cerebral
artery occlusion model [29], hence showing that our
method and proteomic method enable to identify
markers of ischemia. The biological network of the
characterized markers was established using CytoScape
shareware [30]. Interestingly, several markers were in-
terconnected (Figure 1B) and highlighted the potential
signaling pathways that are deregulated during ische-
mia. Thus, at the intersection of several markers are sig-
naling pathways related to GLUT4/Slc2a4 glucose
transporter, MAPK3/ERK1 signaling and HSP90 which
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However, our principal objective herein was to isolate and
identify few markers that were modulated following Ator-
vastatin or Fenofibrate treatments and more precisely, that
preserve of were restored to control levels in ischemia-
reperfusion pre-treated animals. In this latter category, we
found the protein disulfide isomerase A3/Erp60, the Janus
kinase 2 as well as markers found in neurodegenerative
diseases such as Parkinson’s disease (α-synuclein and




Referred to figure 2A, we observed a statistically significant
decrease of the cortical expression of α-synuclein of
atorvastatin-treated rats when compared to the control
group. (OD ratio: Control group: 0.12 ± 0.01, Atorvastatin-
treated group: 0.08 ± 0.02, p < 0.05). α-synuclein expression
in I/R group was reduced (OD ratio: 0.07 ± 0.05) but not
significantly when compared to control. With regards to
fenofibrate-treated I/R rats and atorvastatin-treated I/R










































Figure 2 Cortical expression of α-synuclein (2A), 14-3-3 Zeta (B) and T
quantification of α-synuclein and 14-3-3 Zeta (KCIP-1) and TUC-4 expression in
group). Statistical analysis using ANOVA followed by Fisher’s LSD test: ★ indicaexpression of brain cortical α-synuclein expression. But
the observed decrease in both fenofibrate-treated or ator-
vastatin group was not statistically significant (OD ratio re-
spectively: 0.09 ± 0.01; 0.10 ± 0.01). α-synuclein can form
intracellular aggregates when it is produce in excess lea-
ding to the formation of the Lewy bodies in the neuronal
cytoplasm [31]. Accumulation of aggregated α-synuclein is
one of the major causes of neuronal death in Parkinson
disease and the loss of α-synuclein have been described in
a model of perinatal hypoxia/ischemia [29] suggesting a
sensitivity of dopaminergic neurons to hypoxia. Interes-
tingly, atorvastatin showed its ability, for the first time, to
lower α-synuclein expression. The mechanisms of the de-
crease are still elusive and several hypotheses are possible,
including the interaction with other proteins or regulation
of lipid metabolism. However, lowering α-synuclein could
be protective toward the potential toxicity of α-synuclein
in neurological disorders remains to be considered as a po-
tential long-term treatment in Parkinson’s disease [32].
14-3-3 Zeta
Concomitantly to the lowering of α-synuclein expres-

























UC-4 (2C) in Control and treated rats. Western blot and
the brain cortex. Results are expressed as mean ± sem (n = 6 in each
te a p value <0.05 vs. control group.
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ing the experimental groups. As shown in figure 2B, 14-
3-3 ζ expression was dramatically increased in the brain
submitted to an ischemia-reperfusion procedure when
compared to the control group (OD ratio: control group:
1.81 ± 0.37; I/R group: 5.34 ± 3.86; p < 0.05). To a lesser
extent, we observed a moderate increased expression
of 14-3-3 ζ when the rats were submitted to a pre-
treatment by atorvastatin during 14 days before I/R (OD
ratio: control group: 2.87 ± 0.67), which was not statisti-
cally significant. However, a 14 days fenofibrate treat-
ment had no significant effect on 14-3-3 ζ expression
level (OD ratio: 1.60 ± 0.09). Surprisingly, the effect of
ischemia-reperfusion injury on 14-3-3 zeta increased ex-
pression was abolished under both fenofibrate or atorva-
statin treatment. The hypolipidemic drugs treatment
tends to diminish the expression of 14-3-3 ζ in the cor-
tex (OD ratio: I/R Feno: 1.67 ± 0.18; 1.28 ± 0.07) when
compared to control even if this lowering was not statis-
tically significant. A potential role of 14-3-3 ζ in the for-
mation of α-synuclein aggregates was suggested [33].
Even if speculative, we did not evaluate the co expres-
sion in the tissue of both α-synuclein and 14-3-3 ζ, our
results tend to show an inverse correlation between the
expression of α-synuclein and 14-3-3 ζ. The increase of
14-3-3 ζ after ischemia-reperfusion injury may constitute
a mechanism of defense against the toxicity of oxidative
stress induced protein modification, such as the oxidized
α-synuclein [34]. The mechanism of induction of 14-3-3
ζ by atorvastatin therapy remains unknown. One of the
limits of our work is the impossibility to identify the po-
tential role of 14-3-3 ζ in the atorvastatin effect. How-
ever, a growing body of evidence suggest that 14-3-3 ζ
could be a surrogate marker of brain injury; the level of
14-3-3 ζ is increased in cerebrospinal fluid of patient
with Creutzfeld-Jacob disease or Seizure [35]. Addition-
ally, an increased level 14-3-3 ζ in the cerebrospinal fluid
from patients who had been operated of aortic aneurysm
has been described and suggested to be central nervous
markers of ischemic conditions [36]. The normal level of
14-3-3 ζ is restored in ischemia-reperfusion after pre-
treatment with both atorvastatin and fenofibrate there-
fore suggesting that both drugs have potential neuropro-
tective effect and may more rapidly limit the neuronal
injury induced after ischemia. A longitudinal study of
patients treated with lipid lowering drugs and who faced
an ischemic episode would be useful to acknowledge the
potential neuroprotective effect of such drugs.
TUC-4
TUC-4 (dihydropyrimidinase-like 3, also referred to as
Ulip1 or CRMP4 or TOAD) expression was increased
in I/R condition. The protein TUC-4, as referred to
Figure 2C showed a dramatic cortical increased expressionwhen compared to the control group (OD ratio: Control
group: 1.66 ± 0.16; I/R group: 4.84 ± 0.74; p < 0.05). In the
condition used for this study, a 14 days pre-treatment by
fenofibrate had no effect on the basal level of TUC-4 in
the cortex of the animals (OD ratio: 1.63 ± 0.14) whereas
atorvastatin showed a tendency to decrease TUC-4 ex-
pression in the cortex (OD ratio: 1.14 ± 0.10), even if this
lowering did not reach the statistical significance thresh-
old. TUC-4 belongs to a family of proteins expressed du-
ring neurogenesis, especially during the emerging cone
setting and the axonal growth [37]. TUC-4 expression
could rise in case of axonal damage [38]. In our work, we
showed a dramatical increase of TUC-4 expression after
ischemia-reperfusion injury. This result is consistent with
the knowledge concerning TUC-4 and the neurogenesis
after stroke [38]. However, the lack of effect of atorvastatin
on TUC-4 expression was surprising, as atorvastatin is
known to induce neurogenesis and synaptogenesis [39].
This result may be due to a difference in the treatment
period, the treatment start point or the dose of atorva-
statin. In our work, the dose corresponds to 15 mg/kg/
day. In the work of Chen et al., the highest dose was
8 mg/kg/day and was the less effective. Interestingly, the
administration of atorvastatin or fenofibrate before the
ischemia-reperfusion injury leads to a normalization of
the TUC-4 expression. The mechanisms of interaction
between the drugs and ischemia-reperfusion injury are
elusive and difficult to explain. The abolition of ischemia-
reperfusion injury induced-mediators production by
neuroprotective drugs is a hypothesis among others. Some
investigations are needed to evaluate the relevance of such
a result in stroke therapy.
PDI
Found during the proteome exploration, the expression
variation of Protein Disulfide Isomerase A3 (58 kDa iso-
form, Erp60) (PDI) was studied by western blot (Figure 3A).
The PDI is expressed in the cortex of the rat at a basal level.
A 14 days fenofibrate treatment induced a slight but not
statistically significant decrease expression of PDI (OD
ratio: Control group: 1.57 ± 0.22; fenofibrate: 1.05 ± 0.16). A
14 days Atorvastatin treatment was more effective and in-
duced a dramatic decrease of expression of PDI when
compared to control (OD ratio: 0.78 ± 0.08, p < 0.05). Fol-
lowing Ischemia-Reperfusion injury, the PDI expression
was enhanced in the cortex even if the statistical signifi-
cance threshold was not reached (OD ratio: 2.18 ± 0.03).
This elevation of PDI expression is reported to be lowered
by anti-inflammatory treatment [40]. The hypolipidemic
drug treatment before ischemia-reperfusion injury had a
lowering effect on the ischemia-reperfusion injury induced
PDI surged expression. Both fenofibrate and atorvastatin
pre-treatments maintained a PDI expression comparable to





























Figure 3 Expression of Protein Disulfide Isomerase in the rat brain. 3A Cortical expression of Protein Disulfide Isomerase (PDI, Erp 60) in
the different groups. Results are expressed as mean ± sem (n = 6 in each group). Statistical analysis using ANOVA followed by Fisher’s LSD test:
★ indicates a p value < 0.05 vs Control group. 3B Expression of PDI in the cortex and striatum 24 hours after reperfusion. PDI is expressed under
basal condition (contra) and only found in pycnotic cell of the penombra under ischemia-reperfusion injury. Striatum cells had a lower level of
expression when compared to cortical cell. 3C The PDI expressing cell were identified as neuron using immunofluorescent double labelling with
an NSE antibody.
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of fenofibrate and atorvastatin of 1.48 ± 0.5 and 1.32 ±
0.04, respectively; p < 0.05).
To further study the PDI expression following ischemia-
reperfusion, we focused on cellular expression of PDI in
the brain of rat as shown in figure 3B. Interestingly, PDI is
expressed preferentially in the cortex of rat, when com-
pared to other brain regions, especially the striatum. In
the basal condition (Contra), PDI positive cells showed a
strong staining of the cell soma close to the nucleus. Such
a localization of the staining is compatible with an endo-
plasmic reticulum subcellular localization of the protein.
After the ischemia-reperfusion injury, the PDI labelling
was modified. In the core of the lesion, where necrotic
death happens very early, PDI staining disappeared within
the cells. In sharp contrast, in the penumbra, a robust PDI
staining was essentially observed in pycnotic cells. The
subcellular localization differed from that observed in
control condition. The PDI was found in the soma and
neuritic extensions. To identify the cellular type of PDI
positive cells, we performed a co-immunostaining with
the neuronal marker Neuron Specific Enolase (NSE), as
illustrated in figure 3C. Interestingly, the PDI positive cells
of the penumbra were also NSE positive, demonstrating
that neurons are expressing the PDI. Together, Western-
blot and immunohistochemistry analyses suggested that
enhanced expression of PDI is resulting from reactive
neurons in the penumbra whereas the core zone of ische-
mia, there is a loss of PDI expression. However, in the
present study the effect of PPARα agonists was likely not
associated with an anti-inflammatory effect [41] since in-
flammatory markers were not herein identify. However,
our study suggests together with that of Llorente and col-
laborators that multiple therapeutic pathways may regu-
late the expression of PDI, and that the repression of PDI
expression or activity may be show promising therapeutic
in ischemia reperfusion. Thus, recent studies have
suggested a protective effect PDI ligands such as
4-hydrobenzyl alcohol against brain ischemia reperfusion
[41, 42] supporting the idea that PDI is likely an interes-
ting pharmacological target for neuroprotection, an fur-
ther study are certainly necessary to detail the underlying
molecular mechanism.
Conclusions
The present study, using a combined pharmacological
and proteomic approach, aimed to decipher with the
major signalling pathway and molecular target useful for
neuroprotective purposes in brain ischemia/reperfusion.
Using two drugs shown to have potential neuroprotec-
tive effects, we thus showed that signalling pathways re-
lated to unfolded protein response could be represent
interesting pharmacological targets such as PDIA3/
Erp60.Materials and methods
Animals and treatments
Male Wistar rats were obtained from Charles River
Laboratories (Charles River Laboratories, Le Bois
d’Arbresle, France). The rats weight range from 280 to
300 g at the beginning of the experiments. The rats had a
free access to food and water during the treatment period.
All animal experiments were performed within the frame-
works of the French legislation and received the approval
of the local ethic committee (Ethic committee of Nord-
Pas-de-Calais for animal experimentation, CEEA, Lille,
France). A group of Wistar rats (n = 12) was submitted to a
treatment by PPARα agonist. This group was fed with a
0.2% fenofibrate-enriched diet during 14 days. A second
group (n = 12) was submitted to a treatment by statin.
Animals (n = 12) were fed during 14 days with 0.1%
atorvastatin-enriched diet. At the same time, a control
group was fed with standard diet. At the end of the two
weeks period, one half of the rats of each group was sub-
mitted to a middle cerebral artery occlusion. For proteo-
mics analyses, 6 animals in each group were used. Animals
were sacrificed by injection of a lethal dose of pentobar-
bital, followed by a transcardial perfusion of ice cold
10 mM phosphate buffered saline (PBS, pH 7.4). Brain
were harvested, immersed in ice cold PBS, forebrain and
cerebrum were discarded, cortex and striatum were dis-
sected, sliced in small pieces and frozen into liquid nitro-
gen. Brain samples were stored at −80°C until use. For
immunohistochemistry analyses, 6 animals in each group
were used. The animals were transcardialy perfused with
cold heparinized (500 U/L) saline solution. Thereafter, ani-
mals were perfused with 4% paraformaldehyde (PFA) in
PBS (pH 7.4). Brains were removed and post-fixed in the
same fixative solution during 4 hrs at 4°C, then processed
for paraffin embedding and cut into 6 μm thick sections.
Middle cerebral artery occlusion method
Animals were anesthetized with chloral hydrate (300 mg/kg,
I.P.) (Sigma-Aldrich, Saint Quentin Fallavier, France).
Cerebral infarcts were produced by a 60 min medial cere-
bral artery (MCA) occlusion followed by a 24 h-reperfu-
sion period [43]. We introduced into the internal carotid
artery a 4–0 nylon monofilament suture with its tip
rounded by flame heating. Under surgical microscope
control, the suture was gently advanced into the internal
carotid artery to occlude the origin of MCA (25 to 30 mm
distal to the carotid bifurcation). After 60 min, the suture
was carefully removed to allow reperfusion. A rectal probe
was inserted and the core temperature was maintained
at ∼ 37°C by the use of a heating pad and a heating lamp.
Two-dimensional gel electrophoresis
For 2D analysis, frozen brain samples were homogenized
in 2D sample buffer using Wheaton glass homogenizer
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Triton X-100 4% v/v, DTT 20 mM. 400 μg of protein were
diluted to a final volume of 400 μL and 0.6% carrier
ampholytes (pH 4–7) and 10 mM Tris (final dilution) were
added immediately prior to protein load. IPG isoelectrofo-
cusing (IEF) was carried out in a Protean IEF cell (Biorad,
Hercules, CA), using a 18 cm pH 4–7 Amersham ready
strip. The IPG strips were rehydrated overnight with the
protein lysate. For subsequent IEF, voltage was increased
gradually to 10.000 V to reach a total of 60.000 V/hr. Im-
mediately after focusing, strips were equilibrated for 3×15
minutes in a solution containing 50 mM Tris, 2% SDS,
20% glycerol, and 1% DTT w/v, and 0.01% w/v Bromophe-
nol blue as tracking dye. SDS-PAGE was performed in a
Protean IIXi Cell (Biorad) on a 12% polyacrylamide gel,
until dye track reach the end of the gels. Gels were
Coomassie’s Brillant Blue-stained for a first analysis,
followed by a silver-staining procedure. Thereafter, stained
gels were digitized and processed using Melanie III two-
dimensional gel analysis software (Genebio, Geneva,
Switzerland) for spot detection and analysis. Spots were
edited manually to remove technical artefacts such as gel
distortion and polypeptides were identified by mass spec-
trometry as previously described [44].
Western blot
For western blot analysis, frozen brain samples were soni-
cated in RIPA lysis Buffer (150 mM NaCl, 6 mM sodium
deoxycholate, 1 mM EGTA, 1 mM Igepal CA-630, 1% ICN
proteases inhibitors cocktail kit, Tris–HCl 50 mM pH 7.4),
mixed with Laemmli reducing sample buffer and heated at
100°C for 5 minutes. 50 μg of protein were loaded onto a
4-12% SDS-PAGE gradient gel and submitted to an over-
night electrophoresis at 20 mA per gel. At the end of the
procedure, proteins were transferred on a nitrocellulose
membrane. After blocking the non specific interaction sites
using 5% milk in 20 mM Tris buffered saline 0.05% Tween-
20 (TBST), pH 7.4, membrane was incubated overnight at
4°C with specific primary antibodies solution at 1 μg/mL
TBST 5% milk (mouse anti-PDI (clone 1D3), SPA-891 from
Stressgen, mouse anti-alpha-synuclein BD610786 from
BD bioscience, rabbit anti- 14-3-3 Zeta SC-1019 from
SantaCruz Biotechnologies, rabbit anti-TUC-4 AB5454 and
pan-TUC ABN108from Chemicon and mouse anti-actin
A2413 from Sigma). Thereafter, antibodies were detected
with species-specific HRP coupled secondary antibodies
(Goat anti-rabbit IgG-HRP AP132P, Goat anti-mouse IgG-
HRP AP127P, from Chemicon) 1/50000 in TBST. Detec-
tion was performed using ECL chemiluminescent system
(Amersham) and LAS3000 lumi-imager (FujiFilm, Japan).
Immunohistochemistry
Paraffin embedded sections were successively deparaffi-
nized with toluene and rehydrated using a classicalprocedure of successive ethanol decreasing grade baths.
Sections were permeabilized by immersion in 0.3% Triton
X-100 in PBS (pH 7.4). Thereafter, endogenous peroxidases
were blocked with 0.3% H2O2 and 10% methanol in PBS
(pH 7.4). Protein nonspecific binding was blocked with 5%
normal horse serum in PBS (pH 7.4). Sections were then
incubated over night at 4°C with a mouse anti-Protein
Disulfide Isomerase monoclonal antibody (5 μg/mL final
dilution, mouse anti-PDI, SPA-891 from Stressgen) and/or
a rabbit anti-Neuron Specific Enolase (5 μg/mL, NA 1247
from Biomol International) in PBS. Antibodies were visua-
lized with an anti-goat Vectastain ABC Elite kit (Vector
laboratories) and DAB/H2O2 exposure (Sigma Fast DAB
tablets set, Sigma) according to the manufacturers’ instruc-
tions. For double labelling, antibodies were visualized using
an Alexa Fluor-422 labelled goat anti-mouse antibody
(A11001) and an Alexa Fluor 565 labelled goat anti-rabbit
antibody (A11011) (1/500 in PBS, Molecular Probes).
Statistical analysis
For statistical data comparison, a standard software
package (PRISM GraphPad for Windows) was used. Va-
riables were compared between different groups with a
one-way variance analysis followed by least significance
difference tests. Statistical tests are considered as signifi-
cant when p ≤ 0.05. All values are given as mean ± sem.
Bioinformatics analysis
The biomolecular interactome and gene ontology ana-
lysis was performed using Cytoskape shareware [30, 45].
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